HIV Infections Clinical Trial
Official title:
Home HIV Testing for Older Adults and Their Family and Community Members: a Three-arm Randomized Controlled Trial in Rural South Africa
Many older adults in rural South Africa still lack knowledge of their HIV status despite a
high probability of infection. Older adults tend to test less for HIV because most HIV
testing and prevention programs have been targeted at younger age groups. Other reasons for
failure to test for HIV include frailty and lack of financial resources to travel to HIV
testing centers. Home-based testing is a powerful approach to bring HIV testing services --
and HIV status knowledge -- to older adults. In real-life health systems, community health
workers, such as the South African community care givers, could potentially provide
home-based HIV testing on a routine basis. In this study, the investigators are trying to
establish the best 'form' for the 'function' home-based HIV testing.
Specifically, the investigators aim to
1. Establish the comparative effectiveness of three home-based HIV testing options among
older adults in rural South Africa
2. Identify spill-over effects of the different home-based HIV testing options to other
adults in the households and communities of the older adults receiving the testing
options
3. Determine the comparative cost-effectiveness of the three home-based HIV testing options
among older adults.
Background In the first wave of a large population-representative study of older adults in
rural South Africa, the 'Health and Aging in Africa: A Longitudinal Study of an INDEPTH
Community in South Africa (HAALSI)' study, large gaps in knowledge of HIV status were found
among participants, coupled with low rates of recent HIV testing and high rates of sexual
behaviour that can lead to acquisition and transmission of HIV. In general, older adults
should test for HIV at least once per year (HIVAge.org), but few do so, in part because
current HIV testing programmes have traditionally focused on young and middle-age adults and
HIV testing facilities are often difficult to access for older populations. Only 17% of older
adults in the HAALSI community reported having tested for HIV in the past 6 months.
Home testing can provide a powerful approach to bring the health systems 'function' of HIV
testing to older adults in rural Africa. In the routine health system, community health
workers, such as the South African community care givers, could provide this 'function' on a
regular basis. Home rapid HIV testing and HIV self-test kits have been intensively studied in
many populations. HIV self-test kits have recently become available as over the- counter
products in South Africa, after the South African Pharmacy Council (SAPC) lifted a ban on
their sale in pharmacies in December 2016.
To date, however, no study has compared head-to-head different 'forms' of home testing for
HIV. In this study, the investigators aim to establish the comparative effectiveness and
cost-effectiveness of three different options of home HIV testing among older adults in rural
South Africa: (1) home delivery of HIV self-test kits, (2) home HIV rapid testing, and (3)
both home delivery of HIV self-test kits and home HIV rapid testing.
Overall, home HIV testing is likely attractive for older adults because it allows testing
without having to visit a health care facility. Home delivery of HIV self-testing kits has
the additional advantage that it allows HIV testing in a place and at a time of one's own
choosing. Home approaches to HIV testing are particularly policy-relevant at this time,
because South Africa and many other countries in sub-Saharan Africa are currently expanding
in re-designing their community health worker programs, through which home HIV testing could
be provided on a routine basis.
Preliminary evidence in this and in other populations have suggested that HIV testing and
linkage to HIV treatment and care improve health care utilization for other non-HIV chronic
care and reduce risky sexual behavior. The investigators will thus not only assess the
effects of the different home HIV testing offers on HIV testing but also assess comparative
effects on healthcare utilization, noncommunicable disease endpoints, and sexual behaviors.
Research Aims
This study thus aims to:
1. Establish the comparative effectiveness of three options for home HIV testing for older
adults in rural South Africa
2. Identify spill-over effects of the different options for home HIV testing to other
adults in the families and communities of the older adults receiving the testing options
3. Establish the comparative cost-effectiveness of the three options for home HIV testing
among older adults.
Study Design Participants in Wave 2 of the HAALSI study will be offered one of three options
(randomly assigned 1:1:1) for home HIV testing: (1) three oral HIV self-test kits with a
brief introduction to HIV self-testing (home HIV self-testing arm), (2) home rapid HIV
testing and counselling (home rapid HIV testing arm), and (3) three oral HIV self-test kits
with a brief introduction to HIV self-testing plus home rapid HIV testing and counselling
(home HIV self-testing and HIV rapid testing arm). The brief introduction to HIV self-testing
will include encouragement of both self-use and onward distribution to household and
community members.
The HAALSI participants were randomized (sample ~3,600; 1,200 individuals in each of the
three arms). Randomization has occurred during routine HAALSI fieldwork visits, using a
pre-programmed randomization process that is integrated into the tablet-based HAALSI
computer-assisted personal interview (CAPI). This randomization was completed during a
three-month period between May and July 2019.
Outcome Assessment The primary outcomes (1-2) and a group of secondary outcomes (3-21) will
be assessed by telephone at 9 months after randomization. Based on the timing of
randomization, primary data collection will take place from February through May 2020. Then,
both the primary and an expanded set of secondary outcomes including several
biologically-measured secondary outcomes (1-25) will be assessed at 18-24 months, during the
subsequent, planned cohort-based data collection (HAALSI Wave 3).
Power Calculation In the first wave of the HAALSI study, the proportion of people having
tested for HIV in the past 6 months (which was about 17%) was measured. Assuming uniform
distribution of testing over time, it would be expected that about 3% of older adults in the
HAALSI population tested in the past month. Based on the HAALSI 1 data, the proportion of
older adults who ever tested for HIV is 65%. Given these estimates for the endpoints in the
control arm, this study is powered to detect a 3 percentage point difference in HIV testing
in the past month and a 6 percentage point difference in ever testing for HIV across the
three arms. For this power calculation the investigators further assumed, 20% loss to
follow-up, 80% power and a significance level for rejecting the Null hypothesis of 0.0167.
This significance level results from the adjustment of the standard 0.05 significance level
for multiple hypothesis testing - each arm compared to each other arm - using the
Holm-Bonferroni method.
Data Analyses The investigators will measure risk ratios for all the binary outcomes in this
study, using modified Poisson regression implemented in generalized linear models with
Poisson distribution and log link. Furthermore, the effect sizes for count outcomes using
generalized linear models with negative binomial distribution and log link will be measured;
the investigators will measure effect sizes for continuous outcomes using generalized linear
models with normal distribution and identity link. All estimations will be adjusted for
clustering of outcomes at the household level as well as for baseline values of the
endpoints. Baseline values of our primary and secondary endpoints will be assessed during the
baseline visit before the HAALSI participants receive the trial exposure.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |